Cereno Scientific nominates drug candidate CS014 in HDACi Program for continued development in cardiovascular disease
Cereno Scientific (XSAT: CRNO B) today announced the nomination of drug candidate CS014 for continued development in the preclinical HDACi (histone deacetylase inhibitor) Program. After completing the first half of the preclinical development program, CS014 was nominated after demonstrating highest potential in cardiovascular disease among a set of similar molecules. CS014 is being developed with the aim to provide a better treatment for patients with cardiovascular disease.
“It is great to announce that we have made good advancement in the preclinical HDACi Program, resulting in the nomination of drug candidate CS014. This program, together with our CS1 program, is unique as it uses an epigenetic modulation platform for cardiovascular disease, based on HDAC inhibition,” said Sten R. Sörensen, CEO at Cereno. “We are one of the first to develop treatments for cardiovascular disease by applying epigenetic modulation. This provides an opportunity to develop safer, better and potentially disease-modifying treatments for cardiovascular disease in a completely new way.”
Drug candidate CS014 originates from the preclinical HDACi Program and acts as an epigenetic modulator based on HDAC inhibition. Epigenetic modulation is a new approach in cardiovascular disease and means a change in gene expression without an actual alteration of genetic material. Since HDACs are found in most cells throughout the body, activation of these can lead to changes in how a person’s genes are expressed within the cells. This can affect key cellular mechanisms and thus increase the risk of disease. Using an HDAC inhibitor, such as CS014, the disease-causing epigenetic changes can be modulated.
The preclinical development program for CS014 is currently ongoing in a research collaboration with the University of Michigan, Ann Arbor, USA. CS014 was acquired from Emeriti Bio in March 2019 and has since been developed in a collaboration between Cereno and Emeriti Bio.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with anti-inflammatory, anti-fibrotic, pressure-relieving and anti-thrombotic properties, all relevant for PAH. In addition, Cereno has two promising preclinical drug candidates targeted at treating cardiovascular disease. CS585 is a stable, selective, and potent IP (prostacyclin) receptor agonist and CS014 is an HDAC inhibitor with epigenetic effects. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.